AZBio
05/03/2015Clinical Trials in Arizona - NuvOx
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.
Learn more at NuvOxPharma.com
AZBio
07/20/2014INanoBio Company Presentation
Bharath Takulapalli, Founder & CEO, INanoBio
INanoBio is developing advanced nano sensor technologies for ultra-fast Genome Sequencing & Personalized Diagnostics. With our unique capability combining both nanotechnology and biomedicine, we aim to develop high-impact solutions for personalized healthcare of the future.
AZBio
05/11/2015Clinical Trials in Arizona - Project HoneyBee
About Project Honey Bee: Recent advances in information technology and explosive growth in sophisticated but inexpensive data capture devices—biosensors—promise to revolutionize our ability to detect, diagnose, and prevent disease. By developing the ability to continuously record physiological parameters, we will pinpoint the transition from health to disease and intervene more effectively for improved health outcomes at a reduced cost. Importantly, our validation process is disease, device, and outcome-agnostic, particularly one that can handle the large variety of devices for clinical settings. We leverage our extensive experience in the careful validation of biomarkers for clinical application with a parallel methodology aimed at the utilization of physiological metrics obtained from wearable biosensors to address key clinical problems. To accomplish this goal, we enlist the considerable multidisciplinary resources of Arizona State University, while partnering with health systems such as the Mayo Clinic and Banner Healthcare in the United States and with Chang Gung University and Hospital system in Taiwan.
AZBio
06/21/2014Advancing Innovation Thru Public Private Partnerships - Critical Path Institute
Martha Brumfield, PhD – President & CEO
The Critical Path Institute
Public Private Partnerships were envisioned by the FDA 10 years ago in their report “Stagnation and Innovation” and C-Path is one of the few organizations that has successfully implemented parts of this vision. The uniqueness of being a “neutral, third-party” enticed competitive biopharmaceutical companies to join together in sharing expertise and actual data toward the greater benefit for advancing techniques to develop medicines faster and get them to the patients who are waiting. FDA, EMA and PMDA have collaborated in each of C-Path’s 7 global consortia in offering advice toward a formal regulatory acceptance of new tools and methods. The presentation will review successes from two of these consortia which are focused on developing biomarkers and modeling and simulation tools to expedite new treatments for Alzheimer’s disease and Polycystic Kidney disease.
AZBio
07/14/2014Valley Fever Solutions
Valley Fever Solutions, Inc. (VFS, an Arizona corporation), is developing Nikkomycin Z (NikZ) as a dramatically superior potential cure for Valley Fever. This is a painful and debilitating orphan disease causing over 2,000 serious cases and 150 deaths a year. About 60,000 people are sickened each year, suffering for months. Victims with more serious cases suffer for years.
AZBio
01/08/2014The Value of Medical Technology
AZBio Members are driving value in medical technology innovation.
AZBio
10/19/2013What happens when we embrace possibilities
AZBio president and CEO Joan Koerber-Walker shares what happens when we embrace possibilities and how together we can achieve our goals.